7,436.50

+34.50

+0.47%

51,753.00

+368.00

+0.72%

27,168.50

+83.25

+0.31%

Russell 2000 Futures

2,781.30

+20.80

+0.75%

4.8590

+0.0220

+0.45%

25.64

-2.54

-9.01%

4,129.50

+54.60

+1.34%

74,440.12

-1,284.61

-1.70%

Crude Oil Dec 26

90.37

-0.46

-0.51%

US Private Equity

10,772.76

+11.83

+0.11%

HKSE - Delayed Quote HKD

TransThera Sciences (Nanjing), Inc. (2617.HK)

8.145 +0.060 (+0.74%)

As of 11:59:50 AM GMT+8. Market Open.

Yochanra®, the World's First Innovative Drug to Overcome FGFR Inhibitor Resistance, Makes Its Global Debut in China

PR Newswire 3mo ago

2617.HK
+0.74%
NEW DRUG APPLICATION FOR TINENGOTINIB TABLETS ACCEPTED BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

PR Newswire 10mo ago

2617.HK
+0.74%
TransThera Sciences (Nanjing) (SEHK:2617): Taking Stock of Valuation After a Sharp Multi‑Month Rally

Simply Wall St. 10mo ago

2617.HK
+0.74%
TransThera Publishes Clinical Studies of Tinengotinib (TT-00420) against Cholangiocarcinoma on Lancet

PR Newswire 10mo ago

2617.HK
+0.74%
INCLUSION OF TINENGOTINIB TABLETS IN THE LIST OF PRODUCTS FOR PRIORITY REVIEW BY THE NATIONAL MEDICAL PRODUCTS ADMINISTRATION

PR Newswire 10mo ago

2617.HK
+0.74%

Mobilize your Website

View Site in Mobile | Classic

Share by: